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ABSTRACT
Systemic autoimmune diseases such as systemic lupus
erythematosus (SLE) and rheumatoid arthritis (RA) show significant
heart involvement and cardiovascular morbidity, which can be due to
systemically increased levels of inflammation or direct autoreactivity
targeting cardiac tissue. Despite high clinical relevance, cardiac
damage secondary to systemic autoimmunity lacks inducible rodent
models. Here, we characterise immune-mediated cardiac tissue
damage in a new model of SLE induced by topical application of the
Toll-like receptor 7/8 (TLR7/8) agonist Resiquimod. We observe a
cardiac phenotype reminiscent of autoimmune-mediated dilated
cardiomyopathy, and identify auto-antibodies as major contributors
to cardiac tissue damage. Resiquimod-induced heart disease is a
highly relevant mouse model for mechanistic and therapeutic studies
aiming to protect the heart during autoimmunity.
KEY WORDS: Autoimmunity, Dilated cardiomyopathy, Heart
disease, Myocarditis, Model, Resiquimod, Toll-like receptor 7/8
INTRODUCTION
The immune system is crucially involved in the maintenance of tissue
homeostasis and the response to tissue damage. However, when it is
activated by self-antigens, the immune system causes tissue damage
itself and leads to autoimmune disease. Autoimmune and
cardiovascular diseases are generally considered to affect distinct
demographic groups. However, autoimmune patients have a
substantially increased risk of developing cardiovascular
complications, as well as a significantly worse prognosis after
myocardial infarct compared with the general population (McCoy
et al., 2013). Pharmacological treatment of autoimmune patients
naturally focuses on the management of the autoimmune condition;
however, the major cause of death in autoimmune patients is in fact
related to cardiovascular problems (Jastrzębska et al., 2013).
Involvement of the cardiovascular system in systemic autoimmune
disease results from direct target-specific tissue damage due to
autoreactive effector cells and antibodies, as well as from indirect
damage due to increased systemic levels of inflammatory cytokines
(Abou-Raya and Abou-Raya, 2006; Abusamieh and Ash, 2004;
Knockaert, 2007).
The most common cardiac complication of the prototype systemic
autoimmune disease systemic lupus erythematosus (SLE) is
pericarditis, followed by myocarditis or myocardial fibrosis due to
infiltration of inflammatory cells (Jastrzeb̨ska et al., 2013).
Myocarditis may be idiopathic, infectious or autoimmune in origin.
Inflammation may resolve or persist and lead to cardiac remodelling,
ventricular dilation with normal or reduced left ventricular wall
thickness, and systolic dysfunction, which in turn, leads to dilated
cardiomyopathy (DCM) (Kawai and Matsumori, 2013; Magnani and
Dec, 2006). HistologyonDCMpatient biopsies, showsmyocyte loss,
compensatory hypertrophy, fibrous tissue and chronic inflammation
(myocarditis) in 30-40% of cases (Caforio et al., 2013). Over time,
myocarditis may develop into dilated cardiomyopathy and heart
failure (Baldeviano et al., 2010; Cihakova and Rose, 2008; Eriksson
and Penninger, 2005; Knockaert, 2007), and is therefore a significant
source of morbidity and mortality.
Epicutaneous application of the Toll-like receptor (TLR) 7/8 agonist
Resiquimod (R848) has recently been presented as a new model for
SLE (Yokogawa et al., 2014). The authors elegantly demonstrated the
presence of auto-antibodies and multi-organ involvement. A role for
plasmacytoid dendritic cells (pDC) and TLR7 was confirmed by in
vivo pDC depletion studies and studies using TLR7-deficient mice,
respectively. The authors suggested that interferon (IFN)-α production
by skin-infiltrating plasmacytoid dendritic cells, which promotes B-
cell expansion and maturation and activates myeloid cells and
autoreactive T-cells, as the underlying mechanism for the induction
of systemic autoreactivity (Yokogawa et al., 2014).
Here, we present a thorough functional, phenotypic and mechanistic
characterisation of the cardiac effects of Resiquimod-induced
autoimmunity to establish an inducible mouse model for cardiac
involvement in systemic autoimmune disease and introduce a new
mouse linewith increased susceptibility comparedwith parental strains.
RESULTS
Resiquimod-induced systemic autoimmunity causes left
ventricular dilation and affects heart function
A recombinant inbred mouse line derived from C57BL/6J, FVB/NJ
and NOD/ShiLtJ parental lines was treated with Resiquimod to
induce systemic autoimmunity. This mouse line, hereafter referred
to as CFN, was obtained initially as a control for a different study
and showed notable sensitivity to Resiquimod with clinical signs
including anaemia (pale skin), skin haemorrhages, decreasedReceived 15 August 2016; Accepted 18 January 2017
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urinary output, reduced mobility, piloerection, increased breathing
rate and hunched posture after only 2 weeks of treatment. This was
striking, as the authors of the first report of Resiquimod treatment to
induce systemic autoimmunity (Yokogawa et al., 2014) described
treatment durations of up to 8 weeks in FVB/NJ and BALB/C
mouse strains. Importantly, these signs of acute disease were
transient and resolved within a few days. We therefore used three
Resiquimod applications per week for 2 weeks as standard treatment
in all subsequent experiments.
To determine if the Resiquimod model was suitable to investigate
cardiac involvement in systemic autoimmune disease, cardiac
function upon treatment was measured by echocardiography and
magnetic resonance imaging (MRI; Fig. 1). CFN mice were treated
for 2 weeks with Resiquimod and monitored by echocardiography
over 2 week intervals for up to 8 weeks (Fig. 1A,B). They showed a
consistent decrease in left ventricular (LV) ejection fraction and
fractional shortening (FS), as well as an increase in LV end-systolic
and end-diastolic volumes (ESV and EDV, respectively), while LV
mass remained largely unchanged (Fig. 1B). Diastolic function
assessed by Doppler echocardiography measurements of early (A)
and late (E) ventricular filling velocities across the mitral valve also
remained unchanged (Fig. 1C) and no signs of conduction
abnormalities were observed on electrocardiograms (Fig. S1).
As echocardiography yielded significant differences only at later
stages, we performed MRI, which is considered a more accurate
method for assessment of cardiac function (Stuckey et al., 2008), to
detect subtle differences at earlier stages (Fig. 1D,E). A significant
drop in ejection fraction was detectable as early as week 2 after the
start of treatment. In line with echocardiography results, we
observed a striking increase in LV volume, whereas LV mass
remained unchanged (Fig. 1E). The morphological changes in the
LV culminate in functional impairment, as shown by progressively
Fig. 1. Resiquimod treatment induces morphological changes and functional impairment of the heart. (A) Examples of m-mode traces of a heart from a
Resiquimod-treated mouse compared with traces of a control mouse heart. (B) Quantification of LV end-systolic and end-diastolic volumes (ESV and EDV),
LV mass, fractional shortening and ejection fraction in Resiquimod-treated mice measured at baseline, and at 2 week intervals until week 8. (C) Diastolic function
of Resiquimod-treated mice over time assessed by Doppler echocardiography measurements of early (A) and late (E) ventricular filling velocities across the
mitral valve. For B and C n=8/time point (week 8: n=3), data pooled from two independent repeats. (D) Cardiac MR images demonstrating how parameters of
cardiac structure and function were assessed. 10-framemovies including end diastolic and end systolic images of 7 cross-sections (white lines) from base to apex
were acquired and segmented to obtain the outer and inner border of the LV to determine end diastolic and end systolic mass (EDM, ESM), and EDV and ESV, as
well as ejection fraction. (E) Quantification of LV ESV and EDV, LV mass and ejection fraction in Resiquimod-treated mice measured at baseline and 2 and
4 weeks after the start of treatment. n=5/group, two independent repeats. Values represent mean±s.e.m.; *P<0.05, **P<0.005, one-tailed, paired Student’s t-test.
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decreased fractional shortening (measure of LV stiffness and
contractility) and a reduced ejection fraction (measure of LV
contractility).
These features of myocardial dysfunction and LV dilation with
largely unchanged LVmass are indicative of dilated cardiomyopathy,
and have been observed in patients with underlying autoimmune
disease. Dilated cardiomyopathy can develop secondary to
myocarditis (Cihakova and Rose, 2008; Eriksson and Penninger,
2005), and has been observed in SLE, systemic sclerosis,
dermatomyositis and Churg–Strauss syndrome (Chen et al., 2014;
Elliott, 2000; Jeong et al., 2015; Quartier et al., 2002; Zhang et al.,
2012).
Fig. 2. Resiquimod treatment induces cardiac tissue damage as seen in autoimmunedisease. (A) Splenomegaly as ameasure of systemic immune activation
2 and 4 weeks after start of treatment. (B) Macroscopic observation of morphological changes, severe hyperaemia and haemorrhagic lesions of hearts ex vivo
2 weeks and corresponding quantification 2 and 4 weeks after start of treatment. Macroscopic haemorrhagic lesions were scored on a scale according to: no lesions
(=); lesions cover <10%of heart surface (1); lesions cover 10-30%of heart surface (2); lesions cover 30-50%of heart surface (3); lesions cover >50%of heart surface
(4). (C) Heart/body mass ratio 2 and 4 weeks after start of treatment. (D) H&E-stained paraffin-embedded heart sections (top) showing eosinophilic cardiomyocytes,
islands of hyperaemia and extravasation of red blood cells (RBC), cardiomyocyte (CM) vacuolisation and mononuclear cell infiltration as indicated by black arrows
400× magnification. Original micrograph is cropped to show an example of the respective damage parameter. Corresponding semi-quantitative scores are shown
below. (E) PicoSirius Red-stained frozen heart sections showing epicardial, interstitial and perivascular fibrosis. Top row: 200× magnification; bottom row, 3.3×
magnification of area of interest in panel above. Individual cardiac damage parameters were scored on a scale from 0 to 3 (none, mild, moderate, severe) in five fields
of view in four heart cross-sections at papillary muscle level per mouse. n=4-10/group (each symbol represents one individual mouse), one representative
experiment shown of >3 independent repeats. Values represent mean±s.e.m. *P<0.05, **P<0.005 and ***P<0.001, two-tailed, unpaired Student’s t-test.
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Resiquimod-mediated inflammation induces severe cardiac
tissue damage and recapitulates cardiac symptoms of
human systemic autoimmune disease
Yokogawa et al. (2014) suggested that Resiquimod treatment
induces cardiac tissue damage as part of the systemic autoimmune
syndrome. As cardiac damage and the resulting phenotype were not
studied in detail, we aimed to characterise its molecular and cellular
aetiology. Upon necropsy, mice treated with Resiquimod showed
severe splenomegaly (Fig. 2A) and enlarged hearts with a rounded
shape and remarkable haemorrhagic lesions as early as 2 weeks after
treatment (Fig. 2B). Initial in vivo imaging results (Fig. 1) showing
dilation of the left ventricle rather than thickening of the cardiac
muscle (hypertrophy), are congruent with a comparably minor
increase in heart/body mass ratio at later stages, compared with
untreated mice (Fig. 2C). Histopathological analysis (Fig. S2) of the
hearts revealed significant damage to the whole heart, most
prominently in the endocardium and myocardium and the
papillary muscles. Cardiomyocyte damage and cell death was
evident through (1) increased intensity of eosinophilic staining and
fragmentation (cardiomyocyte apoptotic bodies) (Beranek, 2001),
(2) cardiomyocytes with intracellular vacuolisation, (3) oedema and
(4) red blood cell extravasation, indicating capillary damage
and immune cell infiltration (Fig. 2D), as well as (5) epicardial,
interstitial and perivascular fibrosis (Fig. 2E). These features
resemble autoimmune pancarditis in SLE patients, which is
characterised by interstitial oedema, immune cell infiltration into
the myocardial interstitium, epicardium and endocardium, and areas
of myocyte necrosis and fibrosis (Bulkley and Roberts, 1975;
Busteed et al., 2004; Duan et al., 2013; Salomone et al., 1989). Acute
haemorrhagic myocarditis has also been reported as a complication
in SLE (Dickens et al., 1992). Myocardial lesions with necrosis and
replacement fibrosismay progress to chronicmyocarditis and dilated
cardiomyopathy (Wijetunga and Rockson, 2002).
The Resiquimod model is thus a suitable model to study all stages
of heart disease secondary to systemic autoimmunity, starting from
acute myocarditis to later chronic stages of cardiac remodelling
towards LV dilation and heart failure.
Resiquimod treatment induces a cellular immune response
dominated by lymphocytes in the heart and peripheral
lymphoid organs
One of the salient effects of an autoimmune response is an increase
of immune cell infiltration into affected organs and tissues (Askanas
et al., 1994; Dosreis, 1999; Koo et al., 2013; Lafyatis et al., 2007;
Sun et al., 2013). To determine the extent to which Resiquimod
treatment causes immune cells to infiltrate the heart, which
consequently could be directly responsible for the observed
cardiac damage, CFN mice were treated with Resiquimod for
2 weeks and the heart, mediastinal lymph nodes and spleens were
harvested at 1 week post-treatment for flow cytometric analysis. In
the heart, the total number of CD45+ haematopoietic cells per gram
of tissue increased upon treatment with Resiquimod. This was
largely due to increased CD19+ B-cell and CD3+ T-cell numbers,
while overall levels of CD11b+ myeloid cells were unaffected
(Fig. 3A). Further analysis of the heart and peripheral immune
organs showed a relative increase in the proportion of lymphocytes
and a significantly reduced proportion of myeloid cells among
hematopoietic cells (Fig. 3B), indicating that the adaptive rather
than the innate immune system is involved in the Resiquimod-
mediated direct cardiac damage. One possible cellular mechanism
to explain this observation is an activation of lymphoid cells in the
peripheral immune organs, followed by migration into the heart.
Although differences did not reach statistically significant levels,
an overall increase in relative numbers of CD11b+ cells in the
mediastinal lymph nodes was observed, suggesting that myeloid
cells are involved in activation of B-cells and T-cells in the lymph
Fig. 3. The Resiquimod-induced cellular immune
response in the heart, mediastinal lymph nodes
and spleen. (A) Representative blots obtained by flow
cytometry showing differences in immune cell
populations in the hearts of control and Resiquimod-
treated mice (left) and corresponding total counts of
CD45+, CD3+, CD19+, CD11b+ immune cells/g heart
tissue in Resiquimod-treated versus untreated mice
(right). (B) Frequency of CD3+, CD19+, CD11b+
immune cells among total CD45+ immune cells in
heart tissue, mediastinal lymph nodes and spleens in
Resiquimod-treated versus untreated mice. n=4/
group, data pooled from two independent
experiments. Values represent mean±s.e.m. *P<0.05
and **P<0.005, two-tailed, unpaired Student’s t-test.
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node, which then migrate and accumulate in the heart. While
application of Resiquimod has been shown to reduce marginal zone
B-cells in the spleen and to increase the activated B-cell population
(Yokogawa et al. 2014), the data presented here suggest the
involvement of the adaptive immune system in inducing cardiac
damage.
Resiquimod-mediated systemic autoimmunity increases
levels of anti-cardiac antibodies in the serum, which are
deposited in the heart
While increased infiltration may not necessarily reflect an active
pathological immune response against the affected organ, the
presence of pathogenic anti-self antibodies is a hallmark of
Fig. 4. Resiquimod induces anti-cardiac auto-antibodies. (A) Levels of anti-dsDNA at week 4 after Resiquimod treatment. (B) ELISA to detect relative levels of
antibody isotypes as indicated (light and heavy chains) in serum of untreated and Resiquimod-treated mice. Data pooled from two independent experiments.
(C) Levels of anti-cardiac auto-antibodies of IgM and IgG isotype. (D) Levels of anti-cardiac auto-antibodies with IgG1, IgG2a and IgG2b heavy chains.
(E-G) Immunofluorescence staining using anti-mouse IgG-Alexa Fluor 488 (E), anti-mouse IgM-FITC (F), anti-mouse IgG1/IgG2a/IgG2b/IgG3 and a secondary
anti-rat IgG-Alexa Fluor 488 (G) to detect in vivo deposited antibodies and immuno-complexes as indicated by white arrows. Green: IgG/IgM/IgG1/IgG2a/IgG2b/
IgG3 staining; red: wheat germ agglutinin staining membranes; blue: DAPI staining of nuclei. 400× original magnification. Areas of interest (a,b in E and a in F):
additional 2× magnification. *P<0.05, **P<0.005, two-tailed, paired/unpaired Student’s t-test.
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autoimmune disease (Suurmond and Diamond, 2015). The
Resiquimod-induced SLE model has been demonstrated to
develop auto-antibodies (Yokogawa et al., 2014) and anti-dsDNA
auto-antibodies can be detected in the serum of Resiquimod-treated
CFN mice (Fig. 4A). To define the potential pathogenic role of
autoreactive B-cells and auto-antibodies in cardiac damage, serum
from Resiquimod-treated mice was analysed for cardiac
autoreactivity and antibody isotype composition. Different
antibody isotypes elicit different immune effector functions and
the presence of specific isotypes such as IgG2a and IgG2b has been
correlated with pathological immune responses in autoimmune
disease (Ehlers et al., 2006; Lleo et al., 2010). We therefore analysed
the change in isotype composition of the circulating antibody
repertoire in Resiquimod-treated animals before and after treatment
by using an ELISA to detect IgG1, IgG2a, IgG2b, IgG3, IgA and
IgM as well as the light chains Igκ and Igλ. While the antibody
isotype repertoire did not change in untreated animals, an increase in
IgM and IgG2a was evident in Resiquimod-treated mice. In
addition, in line with an increase in total antibody levels, both Igκ
and Igλ light chain levels increased dramatically (Fig. 4B; Fig. S3).
Most importantly, levels of auto-antibodies of both IgM and IgG
isotypes that were reactive to cardiac lysate quickly increased in the
Fig. 5. Transfer andmutant studies indicate that adaptive immune cells induce cardiac damage. (A) Donor micewere treatedwith Resiquimod as described
above and spleens and sera were harvested one week after cessation of treatment. 2×107 splenocytes/recipient mouse were pre-stimulated in vitro with 5 μg/ml
concanavalin A for 2 days and injected via the tail vein. 200 μl serum/mouse was injected three times per mouse 1 week apart. Control mice were either treated
with Resiquimod as per standard 2 week treatment protocol or left untreated. Hearts of recipient and control mice were harvested 3 weeks after start of treatment.
(B) H&E- or PicoSirius Red-stained paraffin-embedded heart sections (representative examples) were scored for degree of mononuclear cell infiltration and
fibrosis on a scale from 0-3 (none, mild, moderate, severe) in five fields of view in four heart cross-sections at papillary muscle levels per mouse. (C) Systolic and
diastolic function of ‘Group A’ splenocyte recipient mice 4 weeks after splenocyte transfer. Quantification of LV end-systolic and end-diastolic volumes, LV mass,
fractional shortening and ejection fraction measured at baseline, and after 4 weeks. n=3/time point. Diastolic function assessed by Doppler echocardiography
measurements of early (A) and late (E) ventricular filling velocities. n=3/time point. Values represent mean±s.e.m. *P<0.05, **P<0.005 and ***P<0.001, two-tailed,
paired/unpaired Student’s t-test.
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serum after the start of treatment and were significantly elevated
over background levels by 2 weeks (Fig. 4C). In particular, anti-
cardiac IgG2a, and later, IgG2b antibodies, were significantly
elevated in treated CFN mice (Fig. 4D). Cardiac myosin and
troponin were identified as two specific antigens targeted by auto-
antibodies in serum of Resiquimod-treated mice (Fig. S5).
To confirm that anti-cardiac antibodies have the ability to
reach and bind cardiac structures in vivo, we performed
immunofluorescence staining of IgG isotypes and IgM in frozen
heart sections of Resiquimod-treated mice. We found abundant
in vivo deposition of IgG immune complexes, as shown by a focal
punctate staining along the cardiomyocyte sarcolemma (Fig. 4E,
panel a) as well as overall hazy staining in potentially damaged
cardiomyocytes with a stronger staining along the sarcomeres
(Fig. 4E, panel b). Less abundant IgM complexes followed the same
focal pattern along the sarcolemma as IgG complexes (Fig. 4F).
Interestingly, therewas no detectable complement C3c deposition in
the heart, although both IgG and C3c were readily detectable in the
kidneys (Fig. S4), indicating that C3-independent mechanisms of
damage might be involved. Corresponding to the expansion of
IgG2a and IgG2b isotype antibodies in the serum, the prominent
IgG subtypes deposited in damaged cardiac tissue, contained IgG2a
and IgG2b heavy chains. Very mild staining for IgG1 with a cellular
appearance rather than bright antibody complexes was detectable,
while no IgG3 was found (Fig. 4G). In summary, the observed
increase in B-cell proliferation, with accompanying accumulation
of post-class switching antibodies that bind to cardiac structures
in vivo, suggests a pathological role for the auto-antibody pool.
Resiquimod-mediated cardiac damage is inducible by
adoptive transfer of splenocytes and serum
The increase of IgG2a and IgG2b molecules in the serum and
immune complex deposition in the hearts of Resiquimod-treated
animals strongly indicate a central role of B-cells, as seen in many
systemic autoimmune conditions (Browning, 2006; Lleo et al.,
2010). To distinguish between cellular and humoral effectors in this
response, we treated donor CFNmice for 2 weeks, and harvested the
spleens and sera 1 week post-treatment. Donor splenocytes were
pre-stimulated in vitrowith Concanavalin A following a protocol for
T-cell-dependent transfer of myosin-induced myocarditis (Myers
et al., 2013) and injected intravenously into recipient mice. Donor
serawere injected into a separate group of recipient mice following a
slightly modified protocol of passive serum transfer (Bonney et al.,
2013). As controls, donor-cell-free mice were either left untreated
(negative control) or treated with Resiquimod (positive control).
Fig. 5A illustrates the experimental design.
Strikingly, splenocyte transfer faithfully recapitulated the
Resiquimod-induced heart disease phenotype. Injection of
antibody-containing serum from Resiquimod mice produced the
same qualitative pattern of damage, albeit with a milder response
(Fig. 5B). Splenocyte transfer also recapitulates morphological and
functional changes in the heart, with significant LV dilation and a
reduction in ejection fraction 4 weeks after the start of treatment
(Fig. 5C). Notably, effects on heart morphology and function
seemed to be more pronounced and homogenous between treated
individuals compared with direct Resiquimod treatment. This not
only proves the potent involvement of cellular immunity in the
induction of heart disease, but also provides an alternativemethod to
induce Resiquimod-mediated damage, as well as the basis for a
thorough investigation of the cell populations involved.
Since cells and sera were harvested from donor mice 1 week after
Resiquimod treatment, transfer of the agent from the donor to the
recipient was unlikely. While it cannot be excluded that other serum
factors are involved in disease induction, specific anti-cardiac
antibodies (Fig. 4) are a very likely aetiology of disease transmission.
Genetic differences determine immune responses to
Resiquimod treatment and the severity of cardiac damage
Cardiac damage was observed first in mixed-background CFN mice.
To investigate which parental strain might have been the source of
high susceptibility to cardiac damage, parental strains of C57Bl/6J,
FVB/NJ andNOD/ShiLtJ genetic backgroundwere also treated using
the 2 week Resiquimod regime optimised for CFN mice. All three
parental strains responded with severe systemic inflammation as
measured by a substantial increase in spleen/body mass ratio
(Fig. 6A). However, increased levels of anti-dsDNA antibodies
over baseline are only detectable in CFN and NOD/ShiLtJ strains
2 weeks after the start of treatment (Fig. 6B). Most importantly,
although the degree of cardiac damage varied and did not correlate
with the degree of systemic disease severity, all strains did develop
significant inflammatory infiltration and fibrosis in their hearts
(Fig. 6C). For example, while C57Bl/6J showed the highest increase
in spleen/body mass ratio, immune cell infiltration into the heart was
lower as compared with the other strains. Comparable to CFN mice,
noneof the parental strains had a detectable increase in heart/bodymass
ratio by week two (Fig. 6D), although the hearts appeared enlarged at
necropsy. Notably, none of the parental strains developed significant
functional impairments. Mild morphological changes indicative of the
onset of LV dilation were observed in individual mice, particularly of
the NOD/ShiLtJ background, but these did not reach statistical
significance (Fig. 6E). These data indicate that there are differences in
both the sensitivity to induction of systemic autoimmunity as well as
susceptibility to a subsequent effect on the heart. There is no direct
linear correlation between the degree of initial systemic inflammation,
the ensuing cardiac tissue damage and the subsequent functional
defects when comparing mice of different genetic backgrounds.
Considering the importance of variations in TLR7 levels for the
susceptibility to autoimmune disease in humans, a potential
involvement of TLR7 in the differences in susceptibility to
Resiquimod-induced heart disease between strains was investigated.
There are currently no single nucleotide polymorphisms known
between the parental strains that could be predicted to cause changes in
protein expression. Strikingly, flow cytometry showed that CFN mice
expressed lower levels of TLR7 in splenocytes compared with the
parental strains C57Bl/6J and NOD/ShiLtJ (Fig. 6F). A highly
variable response of splenocytes to Resiquimod stimulation was
observed in vitro between all four strains (Fig. 6G). However, all three
parental strains showed a strong proliferative response of B-cells while
numbers of T-cells and myeloid cell populations were maintained at
baseline levels or decrease. In contrast, and in line with lower levels of
TLR7 expression, CFN mice showed a less-pronounced increase in
B-cell numbers, but also expanded numbers of T-cells and myeloid
cells in the same culture (Fig. 6H).
Thus, in contrast to our expectations, increased levels of TLR7
expression and generalised immune hyper-responsiveness could not
be detected. Instead, the unique response of CFN splenocytes to
in vitro Resiquimod stimulation, comprising an overall lower
expansion in cell numbers, but a parallel increase in B-cells, T-cells
and myeloid cells, may provide a mechanistic basis for the observed
differences on morphological and functional levels.
DISCUSSION
Several models of primary heart-specific autoimmunity are well
established and widely used, such as experimental autoimmune
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Fig. 6. Genetic variation defines the responses to Resiquimod treatment and the severity of cardiac damage. (A) Splenomegaly as a measure of systemic
immune activation 2 weeks after start of treatment in CFN, C57Bl/6J (B6), FVB/NJ (FVB) and NOD/ShiLtJ (NOD). (B) Levels of anti-dsDNA at week 2 after
Resiquimod treatment. (C) Semi-quantitative scores of degree of mononuclear cell infiltration and fibrosis based on H&E- and PicoSirius Red-stained paraffin-
embedded heart sections. Individual damage parameters were scored on a scale from 0-3 (none, mild, moderate, severe) in five fields of view in four heart cross-
sections in the myocardium at papillary muscle level per mouse. (D) Heart/body mass ratio 2 weeks after start of treatment. (E) Quantification of LV end-systolic
volumes, LV mass, fractional shortening and ejection fraction in Resiquimod-treated mice measured at baseline (CTRL) and 6 weeks after start of treatment
(Resiquimod). n=5. (F) Expression level of TLR7 in splenocytes asmeasured bymean fluorescence intensity (MFI) using flow cytometry; n=5. (G) Total cell count
in culture at day 4 of splenocytes stimulated with 1 mg/ml Resiquimod. (H) Total T-cell, B-cell and myeloid cell counts in culture at day 4 in splenocytes stimulated
with 1 mg/ml Resiquimod obtained by manual counting and flow cytometry staining against CD45+, CD3+, CD19+, CD11b+ immune cells; n=3. Values represent
mean±s.e.m. *P<0.05, **P<0.005, ***P<0.001 and ****P<0.0001, two-tailed, unpaired Student’s t-test. Asterisks directly above individual columns indicate a
significant difference between the respective parental strain and CFN mice.
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myocarditis (EAM) induced by immunisation with cardiac myosin,
and Coxsackie virus B3-induced myocarditis (Ciháková et al., 2004).
However, the field lacks a clinically relevant inducible model of heart
disease that develops secondarily to systemic autoimmunity. Two
models used to induce systemic autoimmunity, namely injection of
pristane (Reeves et al., 2009) and chronic graft versus host disease
(cGVHD) (Tyndall and Dazzi, 2008) have not been investigated for
cardiac damage, and are compromised by their long and variable
period until onset of symptoms (pristane), and severe restrictions due
to genetic background, respectively. (cGVHD).
Resiquimod-induced systemic autoimmunity caused a
morphological and functional cardiac phenotype that resembled
immune-mediated myocarditis and dilated cardiomyopathy in a
variety of autoimmune conditions, including SLE, systemic
sclerosis, dermatomyositis and Churg–Strauss syndrome (Chen
et al., 2014; Elliott, 2000; Jeong et al., 2015; Quartier et al., 2002;
Zhang et al., 2012).
Histopathological analysis of the heart revealed oedema and red
blood cell extravasation into the tissue, cardiomyocyte eosinophilia,
vacuolisation and fragmentation, myofibre separation, immune cell
infiltration and fibrosis. Oedema and interstitial red blood cells are a
tell-tale sign of vessel wall damage, which allows passive leakage of
fluids and cells into the tissue. This is probably an early phenomenon
in the course of Resiquimod-induced cardiac damage, caused by the
pro-inflammatory effects of systemically increased cytokine levels on
endothelial and smooth muscle cells. Signs of damage to larger
vessels in the myocardium were not observed; thus, damaged
capillaries are the likely source of interstitial fluids and red blood
cells. Oedema and red blood cell extravasation have also been
observed in haemorrhagic myocarditis in patients with acute flares of
systemic autoimmunity, thus making the model relevant for the
human condition (Dickens et al., 1992). Cardiomyocyte necrosis,
scattered interstitial immune cell infiltration and focal areas of severe
damage with patches of immune cell accumulation and subsequent
fibrosis, as seen in human autoimmune myocarditis and dilated
hypertrophy, are also evident upon histological analysis (Bulkley and
Roberts, 1975; Busteed et al., 2004; Duan et al., 2013; Salomone
et al., 1989; Wijetunga and Rockson, 2002).
Immune cell infiltration into the myocardium may occur in
response to damage in an attempt to remove debris and repair tissue,
as seen after a myocardial infarct, or as a sign of active immune
autoreactivity against previously healthy tissue structures as seen in
autoimmune responses. Importantly, an immune response to tissue
trauma follows a tightly controlled course of events, with an almost
instant dramatic increase in innate immune cell numbers followed
later by a reduced number of adaptive lymphocytes. It is resolved
quickly in order to avoid additional inflammatory damage (Gallego-
Colon et al., 2015; Ramos et al., 2016; Sattler and Rosenthal, 2016;
Yan et al., 2013). By contrast, immune autoreactivity initiates a
slow-onset vicious cycle of initially milder but widespread damage
and repair attempts, perpetuating and exacerbating damage,
inflammation and autoimmunity (Mackay et al., 2008). Thus,
while the composition of the immune infiltrate after physical
damage is generally defined by the exact time point after damage,
the infiltrate resulting from an autoimmune response is characterised
by the simultaneous presence of both active aggressors and passive
responders, most likely at variable relative levels.
At 3 weeks post-Resiquimod treatment, which is presumably the
peak of infiltration of adaptive immune aggressors, we observed a
modest increase in total immune cell numbers in the heart, with a
clear lymphocyte dominance, especially B-cells, in both total and
relative numbers. Importantly, both B- and T-cells are important
pathogenic components of several autoimmune diseases, including
SLE, type-1 diabetes and rheumatoid arthritis (Askanas et al., 1994;
Dosreis, 1999; Koo et al., 2013; Lafyatis et al., 2007; Sun et al.,
2013). However, the role of B-cells in autoimmune disorders varies:
in type-1 diabetes, they are predominantly professional antigen-
presenting cells (Dörner et al., 2011; Serreze and Silveira, 2003;
Wong et al., 2004), whereas in SLE and rheumatoid arthritis, B-cells
contribute to pathology by auto-antibody production (Dörner et al.,
2011; Marston et al., 2010). Thus the exact role of B-cells in cardiac
damage still needs to be fully determined. Here, we show that
mature, class-switched auto-antibodies against cardiac antigens,
including two well-known targets for cardiac auto-antibodies –
myosin and cardiac troponin I – are present in the serum of
Resiquimod-treated mice. In addition, antibodies with mainly
IgG2a and IgG2b heavy chains, which have been implicated in
pathological immune responses in autoimmune disease (Ehlers
et al., 2006; Lleo et al., 2010), are deposited in damaged hearts.
Importantly, auto-antibodies against antigens in the cardiomyocyte
contractile apparatus, such as troponin and myosin, may also cause
cellular damage and induce a remodelling response in the
myocardium by directly interfering with cardiomyocyte function
(Kaya et al., 2012).
While anti-cardiac antibodies are prominent players, the
additional contribution of antigen presentation or cytokine
production by B-cells is likely. The in vivo transfer studies
presented here show that both splenocytes and serum from
Resiquimod-treated mice can directly induce damage, immune
cell infiltration and fibrosis, and splenocytes also recapitulate
functional effects on the heart. This confirms that the cellular and/or
humoral arm of the immune system are indeed causative in
induction of disease rather than secondary epiphenomena.
The role of myeloid cells in Resiquimod-mediated autoimmunity
is less straightforward. In healthy myocardium, myeloid cells
represent a large part of CD45+ cells (Pinto et al., 2016), and
macrophages in particular have gained prominence as mediators of
repair and regeneration after tissue damage (Pinto et al., 2014;
Tonkin et al., 2015). While the total number of cardiac CD11b+
myeloid cells in the heart does not change in response to
Resiquimod, a slight increase was observed in the mediastinal
lymph nodes. It is therefore likely that Resiquimod treatment
induces both lymphoid and myeloid anti-cardiac autoreactivity in
the mediastinal lymph nodes, at which point predominantly
autoreactive lymphoid cells migrate into the heart and cause tissue
destruction. This scenario is reminiscent of the progression of type-
1 diabetes, where the hub of the immune response is the pancreatic
lymph node and the destruction occurs in the pancreas (Gagnerault
et al., 2002). In the case of cardiac autoimmunity, local lymphocyte
autoreactivity ensures an ongoing cycle of damage and fibrotic
repair, leading to left ventricle adverse remodelling, dilation and a
decline in heart function.
Another aspect making the presented model highly relevant to
human autoimmune disease, is the impact of genetic variation on
disease severity as observed when comparing mouse strains of
different genetic backgrounds. Genetic variation not only defines
the initial severity of systemic inflammation, but also determines the
degree of secondary damage to the heart. The mixed-background
CFN mouse strain has inherited a genome that is highly susceptible
to immune-mediated cardiac damage and will therefore, together
with its parental strains, be useful in investigating the underlying
genetic basis of cardiac involvement in systemic autoimmunity.
In summary, investigation of the cellular and molecular
components of the Resiquimod-induced cardiac autoimmunity
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shows that the cellular lymphoid compartment of the immune
system and/or pathogenic auto-antibodies in the serum are primarily
responsible for the observed phenotype in the heart. This mouse
model is useful to study the cellular immunology of heart damage in
systemic autoimmune disease and represents a tool to test novel
therapies for immune-mediated myocarditis and dilated
cardiomyopathy.
MATERIALS AND METHODS
Mice
Mice used were 8- to 10-week-old males or females; control mice were age-
and sex-matched littermates. Mice were housed in either conventional or
individually ventilated cages in temperature-controlled facilities on a
12 h:12 h light/dark cycle on standard diet. All mouse procedures were
approved by the Imperial College London Ethical Committees and The
Jackson Laboratory InstitutionalAnimal Care andUse Committee andwere in
accordance with national and international regulations. The predominant
mouse line used in this study was derived from a triple cross between C57BL/
6J, FVB/NJ and NOD/ShiLtJ parental lines (CFN line). This line was
obtained initially for a different study by mating Igf1rfl/fl C57BL/6J mice
(Jackson Laboratory, Bar Harbor, ME, USA) with Foxp3Cre transgenic
NOD/ShiLtJ mice (Jackson Laboratory, Bar Harbor, ME, USA)
Foxp3CreIgf1rfl/fl mice were then crossed with IGF-1Ea transgenic FVB/NJ
mice (Semenova et al., 2008). This triple cross was in long-term use for a
different project (Johannesson et al., 2014) and was maintained by sibling
mating for over 10 generations. Littermates not carrying the transgenes were
used to establish the CFN line, which has been used for the present study. The
line has been deposited at The Jackson Laboratories (JR29108).
Resiquimod treatment
Mice were treated with TLR7 agonist Resiquimod (R848; Sigma-Aldrich,
Dorset, UK) by topical application to the ear three times a week as
previously described (Yokogawa et al., 2014). The treatment protocol was
modified slightly to ensure dosing dependent on body mass (100 μg/30 μl
per 30 g body mass which equals 3.4 μg/g body mass in 1:3 ethanol:
acetone) and to adjust duration of treatment to the increased susceptibility of
the CFN mice to treatment (2 weeks). Control mice were treated with 1 μl/g
body mass 1:3 ethanol:acetone mix only. Tissue was generally harvested at
week two, immediately after the end of the 2 week treatment protocol or at
week four, after 2 weeks of recovery. Tissue was isolated after in situ
perfusion with ice-cold phosphate-buffered saline (PBS, Sigma-Aldrich)
through the apex of the left ventricle of the heart to clear blood from heart
chambers and blood vessels.
Macroscopic observations and scoring
After perfusion and excision of the heart, macroscopically visible
haemorrhagic lesions were scored on a scale according to: 0, no visible
lesions; 1, lesions cover <10% of heart surface; 2, lesions cover 10-30% of
heart surface; 3, lesions cover 30–50% of heart surface; 4, lesions cover
>50% of heart surface.
Histology and scoring of damage parameters
Hearts of treated and untreated mice were excised after perfusion as
described above and fixed in 4% formaldehyde overnight, dehydrated in an
increasing gradient of ethanol and embedded in paraffin. Sections were cut
at 5 µm and de-waxed and rehydrated in an ethanol gradient, then stained
with Haematoxylin and Eosin (H&E) and PicoSirius Red/Fast Green. All
reagents were purchased from Sigma-Aldrich. In order to allow efficient
analysis of cardiac damage in a large number of samples, a system of semi-
quantitative scores was established. H&E-stained sections were used to
analyse and score eosinophilia of cardiomyocytes (as a sign of
cardiomyocyte death because Eosin staining is stronger when cytoplasm
gets more acidic), cardiomyocyte vacuolisation (sign of later stages of
cardiomyocyte cell death), extravasation of red blood cells (sign of
endothelial/capillary damage) and mononuclear cell infiltration (sign of
the immune system causing and/or reacting to damage). PicoSirius Red
staining was used to analyse and score fibrosis. Individual parameters were
scored on a scale of 0 (none), 1 (mild), 2 (moderate) to 3 (severe) as shown in
representative examples in Fig. S2. Scores were obtained from five fields of
view along the myocardium at a 100× magnification on four midline cross-
sections per animal by a blinded researcher. Images were captured using a
LMD7000 microscope (Leica Microsystems, Milton Keynes, UK) and
processed using the public domain software ImageJ (NIH; http://rsb.info.
nih.gov) (Schneider et al., 2012).
Echocardiography
Echocardiography was performed as described previously (Gallego-Colon
et al., 2015; Stuckey et al., 2014) using a high-frequency ultrasound system
Vevo 770 (VisualSonics, Toronto, Canada) with a 30 MHz linear
transducer. Images were analysed using Vevo 770 workstation software.
Mice were anaesthetised with 1-2% isofluorane to maintain heart rate at
450±50 bpm. Left ventricular ejection fraction (EF), fractional shortening
(FS), mass (LV mass), end systolic volume (ESV) and end diastolic volume
(EDV) were quantified using m-mode acquisitions in the parasternal short
axis orientation. Diastolic function was assessed using 2D guided pulsed-
wave Doppler acquisitions across the mitral valve in the apical four-chamber
view.
Magnetic resonance imaging
All MRI scans were performed at the Biological Imaging Centre, Imperial
College, London. Longitudinal cardiac MRI was performed before, at
week two and week four after start of treatment. Mice were anaesthetised
with 1-2.5% isoflurane adjusted to maintain the respiratory rate of 65-75
breaths/min. Body temperature was maintained at 37±0.5°C by a heating
mat. Respiration, ECG and body temperaturewere continuously monitored
(SA Instruments, Stony Brook, NY, USA). MRI was performed on a 9.4 T-
BioSpec system (Bruker BioSpin, Ettlingen, Germany) using an 86 mm
inner diameter volume transmit quadrature coil and a mouse heart array
receiver. EF, mass, ESV and EDVwere quantified from a stack of ECG and
respiratory-gated CINE gradient echo images in the short-axis plane (7
slices). The acquisition parameters for CINE measurements were:
repetition time (TR)=RR interval/number of frames (∼10 ms for 11
frames), TReffective=RR interval, echo time (TE)=2.05 ms, flip angle=25°,
slice thickness=1 mm (continuous slices), acquisition matrix=122×122,
field of view=20×20 mm2, leading to a spatial in-plane resolution of
164×164 μm2. In order to ensure animal welfare during long anaesthetic
periods for recovery MRI scans and to exclude passive functional effects
on the heart, mice that did not show a severe clinical phenotype indicating
systemic bleeding and decreased blood volume (ruffled fur, hunched
posture, skin haemorrhages, decreased urinary output) were used for
imaging.
Disease transfer studies
Splenocytes and sera were isolated from CFN donor mice after 2 weeks of
Resiquimod treatment and 1 week of recovery. Splenocytes were pre-
stimulated in vitro with 5 mg/ml Concanavalin A (Sigma-Aldrich), washed
thoroughly with PBS (Thermo Fisher Scientific, Loughborough, UK) and
injected via the tail vein into healthy recipient CFN mice at 2×107 cells/
animal. Serum was stored immediately at −80°C and injected
intraperitoneally at 200 μl/week for 3 weeks. Tissue was harvested
3 weeks after first injection and processed for histology as described above.
Immune cell isolation from the heart and lymphoid tissues
For isolation of cells from heart, lymph nodes and spleen, mice were
perfused in situ with ice-cold PBS through the apex of the left ventricle to
clear blood from the circulation. To generate single-cell suspensions, tissues
were excised, finely minced using surgical scissors on ice and digested with
0.25% collagenase F (Sigma-Aldrich) in RPMI medium for 30 min at 37°C
with gentle agitation as described (Johannesson et al., 2014). After the first
round of digestion, supernatants were filtered through 70 µm filters and
transferred into 10% FBS and 300 U ml−1 DNaseI (Roche Diagnostics,
Burgess Hill, UK) on ice to block enzyme activity and washed twice with
ice-cold PBS for 5 min at 1200 rpm, 4°C. Undigested tissue pieces were
transferred into fresh collagenase solution for a second round of digestion
for 30 min at 37°C.
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For in vitro culture experiments, excised spleens were gently mashed
through a 70 μm cell strainer, washed and subjected to red blood cell lysis
using Red Blood Cell Lysis Buffer (Sigma-Aldrich) according to the
manufacturer’s instructions. The obtained cell mixture was then used for
flow cytometric analysis.
In vitro Resiquimod stimulation
Isolated splenocytes were seeded at a concentration of 2×106/ml in complete
RPMI-1640 medium supplemented with 1% penicillin/streptomycin
solution, 50 μM β-mercaptoethanol and 10% heat-inactivated foetal
bovine serum (FBS); all purchased from Thermo Fisher Scientific. Cells
were treated with 1 mg/ml Resiquimod daily for 4 days. Cells were visually
inspected for signs of activation and harvested on day 4 for counting using a
haemocytometer and flow cytometry analysis of cell populations.
Flow cytometric analysis
Surface staining antibodies used were obtained from BioLegend (London,
UK): anti-mouse CD45 [CD45-APC-Cy7, 103116, clone 30-F11, which
reacts with all isoforms and both CD45.1 (NOD/ShiLtJ and FVB/NJ) and
CD45.2 (C57Bl/6J) alloantigens, lot B185138, 1:800], anti-mouse CD3
(CD3-APC, 100235, clone 17A2, lot B166471, 1:200), anti-mouse CD19
(CD19-FITC, 115505, clone 6D5, lot B131781, 1:200), anti-mouse CD11b
(CD11b-PE, 101207, clone M1/70, lot B166034, 1:400). Antibody
dilutions in cell staining buffer containing 1% TruStain fcX (anti-mouse
CD16/32) antibody were used to stain for pan surface markers of broad
immune cell populations (T-cells, B-cells, myeloid cells). TLR7 expression
was detected after permeabilisation of isolated splenocytes in 0.5% Triton
X-100 in PBS, using a rabbit anti-mouse TLR7 antibody (Abcam, ab45371,
1:500) in MAXblock blocking solution (Active Motif, Carlsbad, CA, USA)
and a goat anti-rabbit IgG-Alexa Fluor 488 secondary antibody (Thermo
Fisher Scientific, A11008, 1:1000). Staining was performed following the
manufacturer’s instructions. Samples were acquired using a BD LSRII
(Becton Dickinson, Oxford, UK) and analysed using Flow Jo v.9.8.5
(Treestar, Ashland, OR, USA) software (www.flowjo.com). Fluorescence
minus one (FMO) controls were used for gating on individual populations as
shown in Fig. S6.
ELISA
ELISA assays were performed to detect anti-cardiac antibodies, to
determine their isotypes and target antigens and to analyse the antibody
isotype distribution in serum of Resiquimod-treated mice.
For anti-heart lysate, anti-myosin and anti-troponin assays, ELISA plates
were coated overnight at 4oC with 1 μg/ml rat cardiac lysate (Novus
Biologicals, Abington, UK), recombinant rat cardiac muscle myosin heavy
chain MyHC-α, or recombinant rat cardiac troponin I (both from
MyBioSource, San Diego, CA, US). Serum from Resiquimod-treated mice
was used in serial dilutions (1:10, 1:100, 1:1000) in triplicate for relative
quantification of antibodies against myosin and troponin. Secondary HRP-
conjugated goat anti-mouse IgM (ab5930), IgG1 (ab97240), IgG2a (ab97245)
or IgG2b (ab97250) all from Abcam were used at 1:10,000, and TMB
Substrate (BioLegend) was used to detect binding.
For relative quantification of antibody isotypes in the serum, a Pierce
Rapid Antibody Isotyping Kit - Mouse (Thermo Fisher Scientific) was used
according to the manufacturer’s instructions, using previously determined
dilutions optimised for individual isotypes (Fig. S3). Optical densities were
measured at 450 nm using a SpectraMAX190 microplate reader (Molecular
Devices, Sunnyvale, CA, USA).
Microscopy
For detection of antibodies and antibody/complement complex deposition in
cardiac and kidney tissue in vivo, 5 µm sections of hearts and kidneys of
Resiquimod-treated mice were stained with goat anti-mouse IgG-FITC
(Sigma, F5387, lot 99H4872, 1:200), anti-mouse IgM-Alexa Fluor 488
(BioLegend, 406521, lot B203057, 1:200), or unlabelled anti-mouse IgG1/
IgG2a/IgG2b/IgG3 (BioLegend, 406601/407101/406701/406802, 1:200) and
a secondary goat anti-rat IgG-Alexa Fluor 488 (BioLegend, 405418, 1:500).
C3 staining was performed using anti-mouse C3c-FITC (Thermo Fisher
Scientific, PAI-29718, lot QL2122721H, 1:50), as described previously (Tarzi
et al., 2002). Sections were counterstained with wheat germ agglutinin
(WGA)-Alexa Fluor 594 (Thermo Fisher Scientific) to label membranes for
15 min at room temperature and mounted in Vectashield mounting liquid
containing DAPI (Vector Laboratories, Peterborough, UK) to label nuclei.
Images were captured using a LMD7000 microscope (Leica
microsystems) and processed using ImageJ.
Statistics
Statistical planning of numbers was based on preliminary results of
macroscopic haemorrhagic scoring (effect size 4). Aiming for a power of
0.95, group sizes of at least three were deemed sufficient to reach statistical
significance. To account for potential experimental losses, at least 5 mice per
group were used when possible. Power calculations were performed using
G*Power 3.1 (Faul et al., 2007) available at http://www.gpower.hhu.de/. For
MRI imaging, animals were selected as described in the MRI section.
Scoring of histopathology was performed by a blinded researcher. Graph
design and statistical analyses were performed using Prism (GraphPad
Software). P-values are presented following GraphPad style as *P<0.05,
**P<0.005, ***P<0.001 and ****P<0.0001. One- or two-tailed unpaired
or paired Student’s t-tests were performed as appropriate.
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Figure S1: Electrocardiograms of Resiquimod-treated compared to control mice.  
Five representative ECG traces each, obtained from Resiquimod-treated mice two 
weeks post-treatment compared to control mice. 
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Figure S2: Scoring chart of histopathological damage parameters. Representative 
examples of Hematoxilin & Eosin or Picosirius Red stained paraffin-embedded heart 
sections showing four severity grades (none = 0, mild = 1, moderate = 2, severe = 3) 
for eosinophilic cardiomyocytes, extravasation of red blood, cardiomyocyte 
vacuolisation and mononuclear cell infiltration and fibrosis. 400x original 
magnification. 
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Figure S3: Pre-optimised dilutions of serum for the detection of different 
antibody isotypes.  Serum from a male four week old mouse was used to titrate each 
isotype in order to determine optimal binding capacity of the ELISA.  The ELISA was 
performed according to manufacturer’s recommendation with serial serum dilutions. 
Signal from IgG2a was above the detection range due to high concentration of the 
antibody in the mouse used.  
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Figure S4: Kidney C3 stain. Immunofluorescence staining of frozen heart and 
kidney sections of Resiquimod treated mice using anti-mouse IgG and anti-mouse C3 
to detect complement binding to immunecomplexes, green: IgG/C3 staining, blue: 
DAPI staining nuclei. 200x original magnification. 
D
is
ea
se
 M
o
de
ls
 &
 M
ec
ha
ni
sm
s 
• 
S
up
pl
em
en
ta
ry
 in
fo
rm
at
io
n
*ca
rd
ia
c	m
yo
sin
*
IgM
 C
trl
 
IgM Ig
R8
48
 
M 
w2
R8
48
 w
4
-0.5
0.0
0.5
0.5
1.0
1.5
aM
H
C
 Ig
M
 (O
D
45
0-
O
D
ze
ro
)
IgG
1 C
trl
IgG
1 R
84
8 w
2
IgG
1 R
84
8 w
4
-0.5
0.0
0.5
0.5
1.0
1.5
aM
H
C
 Ig
G
1 
(O
D
45
0-
O
D
ze
ro
)
IgG
2a
 C
trl
R8
48
 w
4
IgG
2a
 R
84
8 w
2
IgG
1 
-0.5
0.0
0.5
0.5
1.0
1.5
aM
H
C
 Ig
G
2a
 (O
D
45
0-
O
D
ze
ro
)
IgG
2b
 C
trl
R8
48
 w
4
IgG
2b
 R
84
8 w
2
IgG
2b
 
-0.5
0.0
0.5
0.5
1.0
1.5
aM
H
C
 Ig
G
2b
 (O
D
45
0-
O
D
ze
ro
)
ca
rd
ia
c	t
ro
po
ni
n
IgM IgG1 IgG2a IgG2b
IgM
 C
trl
 
IgM Ig
R8
48
 
M 
w2
R8
48
 w
4
0.00
0.05
0.10
0.15
0.20
aT
PN
 Ig
M
 (O
D
45
0-
O
D
ze
ro
)
IgG
1 C
trl
R8
48
 w
4
IgG
1 R
84
8 w
2
IgG
1 
0.00
0.05
0.10
0.15
0.20
aT
PN
 Ig
G
1 
(O
D
45
0-
O
D
ze
ro
)
IgG
2a
 C
trl
IgG
2a
 R
84
8 w
2
IgG
2a
 R
84
8 w
4
0.0
0.1
0.2
0.3
0.4
aT
PN
 Ig
G
2a
 (O
D
45
0-
O
D
ze
ro
)
IgG
2b
 C
trl
R8
48
 w
4
IgG
2b
 R
84
8 w
2
IgG
2b
 
0.00
0.05
0.10
0.15
0.20
aT
PN
 Ig
G
2b
 (O
D
45
0-
O
D
ze
ro
)
Disease Models & Mechanisms 10: doi:10.1242/dmm.027409: Supplementary information 
Figure S5: Presence of auto-antibodies against cardiac myosin and cardiac 
troponin I. Levels of anti-cardiac auto-antibodies in the serum over time as tested by 
ELISA using serum of Resiquimod treated mice against recombinant cardiac myosin 
and cardiac troponin I and detection antibodies of IgM, IgG1, IgG2a and IgG2b 
isotpye. 
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Figure S6: Flow cytometry gating strategy for the quantification of broad 
immune cell populations in the heart. Cells were acquired as total cell population 
after digestion of the heart without additional prior purification. Storage gate was set 
to an area chosen according to the size of the majority of cells in the lymphnode 
control sample to avoid excessive file sizes due to the low number of immune cells in 
the heart. Cell duplicates were excluded by SSC-H/SSC-A and FSC-H/FSC-A gating. 
The CD45+ cell population was obtained from the single cell population. Further 
gating included the CD3+, CD19+, CD11b+ population among total CD45+ cells. 
Gates were set according to FMO control samples.  
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